Skip to main content

AstraZeneca deepens China presence with FibroGen deal

Submitted by admin on
snippet

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there.

Source
BioPharma Dive

AstraZeneca finally drops roxadustat US rights after FDA rejection, trial failure

Submitted by admin on
snippet

AstraZeneca and FibroGen have finally reached the end of the road for their U.S. collaboration on the oral anemia drug roxadustat.

More than two years after a high-profile FDA rejection, AstraZeneca has returned rights to the HIF-PH inhibitor in the U.S. and certain other countries but retained an interest in China and South Korea, where the drug is approved under the brand name Evrenzo.

Source
Fierce Pharma

FibroGen’s anemia pill falls short in blood cancer study

Submitted by admin on
snippet

An anemia pill from FibroGen didn’t help patients with a type of bone marrow cancer stop receiving blood transfusions in a Phase 3 trial, the latest setback for a drug that approved internationally but rejected in the U.S.

Source
BioPharma Dive

After high-profile US rejection for roxadustat, Astellas touts its safety in new pooled analysis

Submitted by admin on
snippet

While anemia med roxadustat’s U.S. fate remains in limbo, FibroGen partner Astellas is trumpeting data that could help clear the air around its disputed safety profile.

In a pooled analysis of four phase 3 studies, roxadustat proved at least as safe as standard of care erythropoietin therapies when it came to patients’ risk of cardiovascular side effects or death, Astellas said Thursday at the 59th Congress of the European Renal Association (ERA).

Source
Fierce Pharma

AstraZeneca, FibroGen can't agree on roxadustat's path forward in chronic kidney disease after FDA rejection

Submitted by admin on
snippet

In the months since the FDA's high-profile rejection for oral anemia drug roxadustat, AstraZeneca and FibroGen have been working to chart a potential path forward for the med in chronic kidney disease (CKD). But the two partners are now split on what that path might look like, leaving dim prospects for a refiling.

Source
Fierce Pharma

AstraZeneca, FibroGen hope to keep their roxadustat dream alive with new FDA meeting

Submitted by admin on
snippet

After an FDA cold shoulder, FibroGen and partner AstraZeneca still aim to pave a way to market for anemia therapy roxadustat—even if it means conducting another clinical trial. The two companies are now betting the drug’s U.S. future on an upcoming meeting with the FDA.

Source
Fierce Pharma

Astellas readies roxadustat for launch

Submitted by admin on
snippet

Amid the delays and mishandling that marked Fibrogen’s attempts to get roxadustat to market in the US, it is easy to forget that a different story lies behind the drug’s progress in Europe. Astellas, which owns rights to the novel anaemia pill in that region and Japan, won broad backing from the EMA last month with no hold-ups.

This is not to say that the EU regulators waved roxadustat through. The EMA requested several additional data analyses and subgroup explorations and asked “many tough questions”, according to Salim Mujais, senior vice-president and head of medical specialties at Astellas. “In my over 20 years in industry this was one of the most rigorous and meticulous processes with regulators,” he told Evaluate Vantage.

Source
EP Vantage

FibroGen, fresh off data manipulation scandal, touts win in cancer patients without revealing data

Submitted by admin on
snippet

FibroGen’s lead drug has cleared another mid-stage study. Or at least the biotech claims it has.

FibroGen, a 28-year-old company whose stock collapsed this past year after it revealed data it had submitted to the FDA was manipulated, said Wednesday that roxadustat, its pill for anemia, successfully treated cancer patients who suffered anemia as a side effect of chemotherapy.

Source
Endpoints

FDA declines to approve FibroGen's anemia drug

Submitted by admin on
snippet

FibroGen Inc said said on Wednesday that the U.S. Food and Drug Administration has declined to approve its treatment for anemia of chronic kidney disease, citing the need for an additional clinical study.

Source
Yahoo/Reuters

FibroGen slides after FDA posted documents ahead of AdCom meeting on Roxadustat

Submitted by admin on
snippet

FibroGen (FGEN -6.3%) is trading lower after the FDA posted a report on Roxadustat ahead of a decision by its advisory committee this week.

Source
Seeking Alpha